DS-6016 / Daiichi Sankyo, Saitama Medical University - LARVOL DELTA

First-In-Human Study to Assess the Pharmacokinetics and Safety of DS-6016a After Single Subcutaneous Injection in Healthy Japanese Adults. (PubMed, Clin Pharmacol Drug Dev) - "No relationship was observed between DS-6016a dose and the development of anti-drug antibodies. DS-6016a had an acceptable safety profile at single subcutaneous doses of 5-1000 mg."

Clinical • First-in-human • Journal • P1 data • PK/PD data • Genetic Disorders • ACVR1

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Daiichi Sankyo Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Jul 2022

Trial completion • Trial completion date